Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.

Klausmeyer P, McCloud TG, Scudiero DA, Currens MJ, Cardellina Ii JH, Shoemaker RH.

Bioorg Med Chem. 2012 Aug 1;20(15):4646-52. doi: 10.1016/j.bmc.2012.06.017. Epub 2012 Jun 16.

2.

RSK2 Binding Models Delineate Key Features for Activity.

Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW, Nguyen TL.

J Chem Pharm Res. 2010;2(5):587-598.

3.

Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis.

Dorjsuren D, Burnette A, Gray GN, Chen X, Zhu W, Roberts PE, Currens MJ, Shoemaker RH, Ricciardi RP, Sei S.

Antiviral Res. 2006 Jan;69(1):9-23. Epub 2005 Nov 18.

PMID:
16337284
4.

Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.

Yang QE, Stephen AG, Adelsberger JW, Roberts PE, Zhu W, Currens MJ, Feng Y, Crise BJ, Gorelick RJ, Rein AR, Fisher RJ, Shoemaker RH, Sei S.

J Virol. 2005 May;79(10):6122-33.

5.

Application of high-throughput, molecular-targeted screening to anticancer drug discovery.

Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA.

Curr Top Med Chem. 2002 Mar;2(3):229-46. Review.

PMID:
11944818
6.

Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.

O'Keefe BR, Shenoy SR, Xie D, Zhang W, Muschik JM, Currens MJ, Chaiken I, Boyd MR.

Mol Pharmacol. 2000 Nov;58(5):982-92.

PMID:
11040045
7.

Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii(1).

Charan RD, Munro MH, O'Keefe BR, Sowder RCII, McKee TC, Currens MJ, Pannell LK, Boyd MR.

J Nat Prod. 2000 Aug;63(8):1170-4.

PMID:
10978222
8.

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE.

Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.

9.

Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.

Currens MJ, Mariner JM, McMahon JB, Boyd MR.

J Pharmacol Exp Ther. 1996 Nov;279(2):652-61.

PMID:
8930168
10.

Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.

Currens MJ, Gulakowski RJ, Mariner JM, Moran RA, Buckheit RW Jr, Gustafson KR, McMahon JB, Boyd MR.

J Pharmacol Exp Ther. 1996 Nov;279(2):645-51.

PMID:
8930167
11.

Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.

McMahon JB, Buckheit RW Jr, Gulakowski RJ, Currens MJ, Vistica DT, Shoemaker RH, Stinson SF, Russell JD, Bader JP, Narayanan VL, Schultz RJ, Brouwer WG, Felauer EE, Boyd MR.

J Pharmacol Exp Ther. 1996 Jan;276(1):298-305.

PMID:
8558446
12.

A reinvestigation of Maprounea triterpenes.

Beutler JA, Kashman Y, Tischler M, Cardellina JH 2nd, Gray GN, Currens MJ, Wall ME, Wani MC, Boyd MR.

J Nat Prod. 1995 Jul;58(7):1039-46.

PMID:
7561897
13.

Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.

Buckheit RW Jr, Fliakas-Boltz V, Decker WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR, et al.

Antiviral Res. 1995 Mar;26(2):117-32.

PMID:
7541618
14.

Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms.

McMahon JB, Currens MJ, Gulakowski RJ, Buckheit RW Jr, Lackman-Smith C, Hallock YF, Boyd MR.

Antimicrob Agents Chemother. 1995 Feb;39(2):484-8.

15.
16.

Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH.

J Virol. 1993 Apr;67(4):2412-20.

17.

The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.

Kashman Y, Gustafson KR, Fuller RW, Cardellina JH 2nd, McMahon JB, Currens MJ, Buckheit RW Jr, Hughes SH, Cragg GM, Boyd MR.

J Med Chem. 1992 Jul 24;35(15):2735-43. Erratum in: J Med Chem 1993 Apr 16;36(8):1110.

PMID:
1379639
18.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine.

Ahluwalia G, Cooney DA, Bondoc LL Jr, Currens MJ, Ford H, Johns DG, Mitsuya H, Fridland A.

Biochem Biophys Res Commun. 1990 Sep 28;171(3):1297-303. Erratum in: Biochem Biophys Res Commun 1990 Nov 30;173(1):481.

PMID:
1977386
19.

Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.

Perno CF, Cooney DA, Currens MJ, Rocchi G, Johns DG, Broder S, Yarchoan R.

AIDS Res Hum Retroviruses. 1990 Aug;6(8):1051-5.

PMID:
2223241
20.
21.

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR.

Cancer Res. 1988 Sep 1;48(17):4827-33.

Supplemental Content

Loading ...
Support Center